Taken together, these results establish the importance of structure-guided protein engineering to designing CAR binding domains with exquisite selectivity and characterize IL13-mutein CAR T cells with enhanced selectivity for IL13Rα2 for potential expansion of IL13-based immunotherapy to malignancies outside of GBM. The gene discussed is IL13; the disease is glioblastoma.